Skip to main content


Fig. 5 | BMC Cancer

Fig. 5

From: Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo

Fig. 5

Anti-CDH11 antibody treatment suppressed tumorigenesis and cancer metastasis, in vivo. a Non-invasive bioluminescence imaging of xenograft mice show the effect of anti-CDH11 antibody treatment on tumor burden, compared to control group. b ‘Tumor burden versus time’ curve depicting the fold change in tumor burden-related bioluminescence over time; *p ≤ 0.05 (c) The effect of anti-CDH11 antibody on distant metastasis incidence in vivo, as shown by bioluminescence imaging. The metastasis incidence is summarized in the Table. d Kaplan-Meier survival curve of the effect of anti-CDH11 antibody on the survival rate of xenograft mice after 6-week experimental period. e Comparative qPCR analysis of CDH11, CD44, vimentin, CTNNB1 and E-cadherin mRNA expression in the primary versus metastatic tumor samples from the control mice. Both primary and metastatic tumor tissues were harvested from the mice at the end of the experiment. The metastatic tumors were mainly harvested from the lungs. W, week post-inoculation; *p < 0.05; **p < 0.01; ***p < 0.001

Back to article page